Skip to main content
Premium Trial:

Request an Annual Quote

Cenix to Analyze Drug Candidates for CellCentric

NEW YORK (GenomeWeb News) – RNAi research services company Cenix BioScience said today it has signed an agreement to help CellCentric validate oncology drug candidates.
 
Dresden, Germany-based Cenix said it will combine high-throughput applications of RNAi-based gene silencing with high-content phenotypic analyses in cultured human cells to provide in vitro validation of several of CellCentric’s drug candidates.
 
Cenix will adapt microscopy-based assays that use an image analysis platform made by Definiens to make discoveries about cellular functions and loss-of-function phenotypes of genes across multiple cell lines.
 
Financial terms of the agreement were not released.

The Scan

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.

Plan Rebuffed

The Associated Press reports China has rejected the World Health Organization's proposal to include the lab-leak theory in the next phase of its investigation into the origins of SARS-CoV-2.

Opossum Change

Researchers from Riken have used CRISPR to edit marsupial genomes, as Technology Review reports.